Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL965868 | 0.89 | EPHX1 (0.59) | CYP2D6CYP2C19EPHX1MAPTMMP1 | |
| SCHEMBL16801793 | 0.87 | CYP2D6 (0.52) | CYP2D6CYP2C19EPHX1MAPTMMP1 | |
| SCHEMBL15148253 | 0.87 | CYP2D6 (0.52) | CYP2D6CYP2C19EPHX1MAPTMMP1 | |
| SCHEMBL18782866 | 0.87 | CYP2D6 (0.52) | CYP2D6CYP2C19EPHX1MAPTMMP1 | |
| SCHEMBL20970337 | 0.86 | — | — | |
| SCHEMBL606666 | 0.86 | — | — | |
| SCHEMBL16650141 | 0.85 | CYP2D6 (0.56) | CYP2D6CYP2C19EPHX1MAPTMMP1 | |
| SCHEMBL22361470 | 0.85 | EPHX1 (0.71) | CYP2D6CYP2C19EPHX1MAPTMMP1 | |
| SCHEMBL10224058 | 0.85 | EPHX1 (0.60) | CYP2D6CYP2C19EPHX1MAPTMMP1 | |
| SCHEMBL777387 | 0.84 | MAPT (0.59) | CYP2D6CYP2C19EPHX1MAPTMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220256854-A1 | PLANT TREATMENT COMPOSITION | CRODA INTERNATIONAL PLC (GB) | 2022-08-18 | — | — | US | claimed |
| EP-3986135-A1 | PLANT TREATMENT COMPOSITION | Croda International PLC (GB) | 2022-04-27 | — | — | EP | claimed |
| WO-2020254104-A1 | PLANT TREATMENT COMPOSITION | CRODA INTERNATIONAL PLC (GB) | 2020-12-24 | — | — | WO | claimed |
| US-20080306237-A1 | Highly Functional, Highly Branched Polyureas | BASF AKTIENGESELLSCHAFT (DE) | 2008-12-11 | — | — | US | claimed |
| EP-1716197-B1 | HIGHLY FUNCTIONAL, HIGHLY BRANCHED POLYUREAS | BASF SE (DE) | 2008-10-29 | — | — | EP | claimed |
| EP-4315479-A1 | METHOD FOR RECYCLING LITHIUM SALTS FROM BATTERIES | ARKEMA FRANCE (FR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117063330-A | Method for recycling lithium salts from batteries | 阿科玛法国公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2022207991-A1 | METHOD FOR RECYCLING LITHIUM SALTS FROM BATTERIES | ARKEMA FRANCE (FR) | 2022-10-06 | — | — | WO | disclosed |
| US-20220256854-A1 | PLANT TREATMENT COMPOSITION | CRODA INTERNATIONAL PLC (GB) | 2022-08-18 | — | — | US | disclosed |
| EP-3986135-A1 | PLANT TREATMENT COMPOSITION | Croda International PLC (GB) | 2022-04-27 | — | — | EP | disclosed |
| EP-0992497-A1 | 1,3-Dialkyl-2-imidazolidinones and a manufacturing process therefor | Mitsui Chemicals, Inc. (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-4611079-A | USEFUL AS ISOCAYANATE PRECURSORS | BASF AKTIENGESELLSCHAFT (DE) | 1986-09-09 | — | — | US | disclosed |
| US-4581451-A | ALKYLATION AND CYCLIZATION OF A URACIL COMPOUND | NESTEC S.A. (CH) | 1986-04-08 | — | — | US | disclosed |
| US-4480110-A | FROM SUBSTITUTED UREAS AND ALCOHOL | BAYER AKTIENGESELLSCHAFT (DE) | 1984-10-30 | — | — | US | disclosed |
| US-4469698-A | SEDATIVES, TRANQUILIZERS | SOCIETE D'ASSISTANCE TECHNIQUE POUR PRODUITS NESTLE S.A. (CH) | 1984-09-04 | — | — | US | disclosed |
| US-4400329-A | Process for the manufacture of thiochlorformates | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1983-08-23 | — | — | US | disclosed |
| US-4388238-A | FROM PRIMARY AMINES, ALCOHOLS, AND CARBONYL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1983-06-14 | — | — | US | disclosed |
| EP-0039780-A1 | Di- or trisubstituted xanthines with neuroleptic activity, process for their preparation and pharmaceutical preparations containing them | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | CYP2D6 650/4885CYP2C19 535/4885EPHX1 635/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | CYP2D6 650/4885CYP2C19 535/4885EPHX1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.